CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival

The US Food and Drug Administration (FDA) has granted the drug CB-839 fast track development status when used in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of drug treatment (including at least one TKI). Fast track status speeds up the review […]

read more

Nivolumab plus ipilimumab for first-line treatment of advanced kidney cancer: Extended 4-year follow-up

Four-year follow up data are now available from the CheckMate 214 clinical trial with the nivolumab plus ipilimumab combination in patients with metastatic renal cell carcinoma (RCC). These data show an improvement in progression-free and overall survival with the nivolumab plus ipilimumab combination compared to sunitinib in the intermediate-/poor-risk patient groups. The durability of the […]

read more

Top stories from 2020 for kidney cancer

Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the Kidney Cancer Programme, at the City of Hope Hospital, California talks about the changes in the management of renal cell carcinoma (RCC) over the past decade. He talks about combination treatments such as nivolumab with ipilimumab, which shows the potential for a complete response in […]

read more

2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]

read more

Individualising first line treatment for advanced kidney cancer

In recent years, a number of new, effective treatments have become available for advanced kidney cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the new treatments do not work for all patients and they […]

read more

Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

Results from the phase 3 KEYNOTE-581/CLEAR trial show that the combination of pembrolizumab plus lenvatinib significantly improved the time taken for the cancer to start growing again (progression-free survival), overall survival, and the response rate compared with sunitinib, when used for untreated patients with advanced renal cell carcinoma (RCC). The pembrolizumab/lenvatinib combination had similar side […]

read more

Approach to selection of first-line treatment for advanced kidney cancer

During this online interview, the approach to selection of first-line treatment for patients with metastatic renal cell carcinoma (RCC) was discussed.  Traditionally, the selection of initial treatments was very straightforward, and patients were treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, (TKIs) such as sunitinib and pazopanib. Over the past 2 years, decisions […]

read more

Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Texas in the USA talks about managing adverse events to immunotherapy and targeted therapy combinations. There are more adverse events from any type of combination treatment compared to single treatments, especially immune adverse events. Nivolumab alone is very well tolerated and quite easy […]

read more

Cabozantinib plus atezolizumab for non-clear cell kidney cancer

In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC. Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not […]

read more

Managing immune-related adverse events

In these video interviews, Dr Eric Jonasch from MD Anderson Cancer Center in Texas and Dr Monty Pal from the City of Hope Hospital in California talk about immune-related adverse events in people with advanced kidney cancer taking combination therapies and immunotherapy: Managing Adverse Events Among RCC Patients Receiving Combination Treatment With Targeted Therapy and […]

read more
Showing 1 to 10 of 116 results
  TOP